Novan's EPI Health Entered into Exclusive License Agreement with Sato Pharma for Rhofade in Japan
Shots:
- EPI Health to receive $5.0M up front, $2.5M in milestones at the time of marketing approval in Japan along with royalty on net sales of the licensed product. Sato will be responsible for obtaining regulatory approval in Japan and obtaining the right to access EPI Health’s US dossier for Rhofade
- Sato to get an exclusive, royalty-bearing, non-transferable right along with a license under EPI Health's IP rights to develop, manufacture and market Rhofade for rosacea in Japan & also has rights of the first negotiation in other countries in the Asia Pacific region
- EPI Health will pay 25% up front & milestones to a third party under contractual obligations related to Rhofade along with the portion of royalty under a license agreement
Ref: GLOBE NEWSWIRE | Image: EPI Health
Related Posts:- Aclaris to Divest its Rhofade (oxymetazoline hydrochloride) with all IPR Rights to EPI Health
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
